Literature DB >> 17123400

Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.

P Komvilaisak1, B Connolly, A Naqvi, V Blanchette.   

Abstract

Frequent infusion of factor concentrates may be challenging in young boys with haemophilia, especially if their disease is complicated by inhibitors. A central venous access device (CVAD) is often placed in young patients in need of repeated infusions for prophylaxis or immune tolerance induction. Although user friendly and capable of providing reliable venous access, these devices are associated with a high complication rate over time. In the haemophilia population, major complications include CVAD-associated infections and deep venous thrombosis, which is most often silent. Established risk factors for catheter-related infection include age less than 6 years at the time of CVAD placement and use of an external CVAD when compared with a totally implantable device such as a port. Avoidance of CVAD-related infections is facilitated by strict adherence to aseptic technique. The risk of deep venous thrombosis appears related to the duration for which the catheter is in place, with the risk increasing beyond 4 years. The promotion of a strict clinic policy in which CVADs are left in place for as short a time as possible should decrease the risk of complications. In rare cases where a totally implantable CVAD cannot be placed for technical reasons, an arteriovenous fistula may provide reliable venous access. In all cases, however, venous access via peripheral veins is preferred over CVADs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123400     DOI: 10.1111/j.1365-2516.2006.01371.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Deep venous thrombosis screening in patients with inherited bleeding disorders and central venous catheters.

Authors:  C R Cost; J M Journeycake
Journal:  Haemophilia       Date:  2011-03-24       Impact factor: 4.287

Review 2.  Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

Authors:  Abha H Athale; Maura Marcucci; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2014-04-24

3.  Treatment of hemophilia: a review of current advances and ongoing issues.

Authors:  Antonio Coppola; Mirko Di Capua; Matteo Nicola Dario Di Minno; Mariagiovanna Di Palo; Emiliana Marrone; Paola Ieranò; Claudia Arturo; Antonella Tufano; Anna Maria Cerbone
Journal:  J Blood Med       Date:  2010-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.